查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2014828

体外诊断品管市场：依产品类型、技术、应用和最终用户划分－2026-2032年全球市场预测

In-Vitro Diagnostics Quality Control Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，体外诊断品管市场价值将达到 16.1 亿美元，到 2026 年将成长至 17.4 亿美元，到 2032 年将达到 28.8 亿美元，复合年增长率为 8.67%。

主要市场统计数据
基准年 2025 16.1亿美元
预计年份：2026年 17.4亿美元
预测年份：2032年 28.8亿美元
复合年增长率 (%) 8.67%

在技​​术融合、监管和日益复杂的营运环境下，品管正成为临床检查室。

本文将体外诊断品管定位为现代临床检查室运作的基石，对病人安全、法规遵循以及临床决策的可靠性至关重要。分析平台的进步、复杂分子检测的激增以及诊断在个人化医疗中日益重要的作用，都凸显了健全的品管系统的重要性。随着检查室和製造商努力实现仪器、试剂和数据系统性能的协调一致，展现出一致的准确性和精密度比以往任何时候都更加关键。

快速的技术、数位化和监管变革如何重塑诊断领域的品管实践以及供应商检查室之间的合作？

在创新、数位化和不断变化的监管环境的交汇点上，体外诊断的品管环境正在加速变革。新兴的仪器平台实现了更高的通量和自动化程度，从而对更精密的品管和试剂配方提出了更高的要求，以检验扩展的动态范围。随着硬体的进步，资料管理和品质保证软体解决方案也在日趋成熟，实现了即时监控和预测分析，从而改变了检查室处理过程控制和偏差管理的方式。

评估 2025 年美国关税变化对诊断药物品管的供应链韧性、筹资策略和营运连续性的影响。

2025年实施的新关税对体外诊断试剂的品管相关的供应链、筹资策略和产品成本结构产生了切实的影响。依赖跨境生产和零件采购的分析仪器、品管样品、试剂和专用软体供应商正在调整其物流和定价模式，以缓解利润压力并维持交货可靠性。为此，采购部门和检查室经理正在重新审视供应商多元化和库存策略，以确保关键品管材料和试剂的持续供应。

将产品类型、技术、应用和最终用户趋势与营运重点和供应商策略联繫起来的全面细分洞察。

深入分析揭示了不同产品、技术、应用和最终用户类别中存在的细微价值提案和营运要求差异，因此供应商和检查室需要製定个人化的策略。依产品类型划分，分析仪器和设备需要专注于系统互通性和维护工作流程。自动化系统可提高处理能力，而半自动化系统则可实现灵活的小规模部署。品管产品必须满足稳定性和基质相容性要求；液体品控品可立即使用，而冷冻干燥品控品则需要长期储存。品管(QC) 试剂需要在不同平台上均具备检验的性能。此外，从资料管理系统和实验室资讯管理系统到专用品质控制软体，各种软体解决方案在确保结果一致性和可追溯性方面正发挥越来越重要的作用，以满足审计要求。

美洲、欧洲、中东、非洲和亚太地区品管解决方案的采购、验证和实施的区域趋势及实际影响

区域趋势影响品管解决方案的采购决策、监管方式和实施管道，而各区域的驱动因素和限制因素又各不相同。在美洲，人们高度重视整合检验网络，并投资于自动化和数位化品管工具，以满足对快速週转和监管可追溯性的期望。相较之下，欧洲、中东和非洲的管理体制和基础设施成熟度则呈现出多样化的特点，既有采用高度复杂管理系统的集中式参考检查室，也有优先考虑成本效益高、稳健可靠且适用于分散式环境的可携式解决方案的小规模机构。

主要企业如何调整其综合产品系列、服务产品和策略伙伴关係关係，以重新定义其在品管的竞争优势？

体外诊断品管领域的主要企业正寻求在技术创新、策略伙伴关係和服务差异化之间取得平衡，以确保与客户建立长期合作关係。市场领导者强调提供整合解决方案，将校准的品管品、相容的试剂和云端软体结合，从而实现无缝的检验工作流程和可审计的报告。与仪器製造商和临床检查室建立策略合作伙伴关係也十分普遍，这有助于共同开发针对特定平台性能特征的品管品，并加速检查室部署。

永续诊断品管中采用的实际优先事项，旨在加强供应链韧性、互通性、人力资源能力和验证支援。

向行业领导者提出的切实可行的建议侧重于加强供应链韧性、提高互通性以及投资人力资源能力，以维持高品质的诊断结果。製造商应优先考虑模组化设计和跨平台检验，以减少相容性障碍并简化检查室采购决策。此外，提高批次追溯和生产来源的透明度将有助于满足监管要求并建立临床客户的信任。这些措施应辅以可扩展的服务模式，包括检验支援、培训和远端监控，从而缩短检查室团队掌握相关技术所需的时间。

为了确保我们的品管结果在实践和技术上的有效性，我们采用了严格的混合方法，结合了访谈、标准分析和三角验证的证据。

本调查方法结合了原始定性资料、二手文献综述以及技术和法规资讯来源的结构化整合，以全面评估品管趋势。原始数据包括对实验室经理、品管和产品经理的访谈，以了解营运挑战、验证实践和采购考量，并透过咨询法规专家来补充对指南和实施趋势的解读。二级资讯来源包括同行评审文献、标准文件和公开的法规文件，这些文件描述了控制设计和验证的技术基础。

投资于互通性人才和供应链透明度将塑造未来诊断医疗设备品管的可靠性和合规性的原因概述。

总之，维护和推广体外诊断品管实践是一项策略性挑战，它支撑着临床可靠性和法规遵循。在技​​术创新、对分子诊断和免疫检测日益增长的依赖以及对数据可追溯性和供应链透明度的不断提高的期望的驱动下，该领域正经历着快速转型。这些因素既带来了挑战，也带来了机会。挑战包括协调不同平台的性能并确保稳健的供应链，而机会则包括利用数位化工具、模组化管理产品和合作伙伴关係来简化验证和监控流程。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：体外诊断试剂品管市场：依产品类型划分

  • 分析仪/设备
    • 自动化系统
    • 半自动系统
  • 标准材料
  • 品控试剂
    • 液体控制
    • 冻干控制
  • 软体解决方案
    • 资料管理系统
    • LIMS
    • 品质控制软体

第九章：体外诊断试剂品管市场：依技术划分

  • 临床化学
    • 比色法
    • 浊度检测法
  • 血液学
    • 自动血球计数器
    • 流式细胞技术
  • 免疫检测
    • 化学冷光免疫检测
    • ELISA
    • 萤光免疫分析
  • 微生物学
    • 文化
    • PCR
  • 分子诊断
    • 下一代定序
    • PCR

第十章 体外诊断试剂品管市场：依应用领域划分

  • 循环系统
    • 心臟标记检测
    • 就地检验
  • 基因检测
    • 携带者筛检
    • 产前检查
  • 传染病检查
    • 细菌检测
    • 病毒检测
  • 肿瘤学
    • 微量残存疾病
    • 肿瘤标记检测
  • 毒理学
    • 滥用药物
    • 治疗监测

第十一章 体外诊断试剂品管市场：依最终用户划分

  • 血库
    • 国家血库
    • 区域血库
  • 诊断实验室
    • 医院检查室
    • 独立检测实验室
  • 医院和诊所
    • 临床检查室
    • 参考检测实验室
  • 研究机构
    • 学术机构
    • 私人实验室

第十二章 体外诊断试剂品管市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 体外诊断试剂品管市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 体外诊断试剂品管市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国体外诊断试剂品管市场

第十六章：中国体外诊断试剂品管市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Grifols, SA
  • Microbix Biosystems Inc.
  • QuidelOrtho Corporation
  • Randox Laboratories Ltd.
  • Roche Holding AG
  • Seracare Life Sciences, Inc.
  • Siemens Healthineers AG
  • Sun Diagnostics, LLC
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Werfen, SA
  • ZeptoMetrix LLC
Product Code: MRR-43127F7279E1

The In-Vitro Diagnostics Quality Control Market was valued at USD 1.61 billion in 2025 and is projected to grow to USD 1.74 billion in 2026, with a CAGR of 8.67%, reaching USD 2.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.61 billion
Estimated Year [2026] USD 1.74 billion
Forecast Year [2032] USD 2.88 billion
CAGR (%) 8.67%

Positioning quality control as a foundational necessity in clinical laboratories amid technological convergence regulatory scrutiny and operational complexity

The introduction frames in-vitro diagnostics quality control as an indispensable pillar of modern clinical laboratory operations, integral to patient safety, regulatory compliance, and the reliability of clinical decision-making. Advances in analytical platforms, the proliferation of complex molecular assays, and the expanding role of diagnostics in personalized medicine have collectively elevated the importance of robust quality control regimes. As laboratories and manufacturers seek to harmonize performance across instruments, reagents, and data systems, the ability to demonstrate consistent accuracy and precision has never been more critical.

This section situates current developments within a broader context of technological convergence and heightened regulatory scrutiny. It highlights the interplay between instrumentation, control materials, and software in creating closed-loop quality management ecosystems. Moreover, it underscores how laboratory leaders and manufacturers are adapting to tighter traceability requirements and expectations for integrated data management. The narrative transitions to a recognition of the sector's operational challenges, including workforce skills gaps, supply chain complexity, and the need for standardized performance metrics, setting the stage for the more detailed analyses that follow.

How rapid technological, digital, and regulatory shifts are reshaping quality control practices and vendor-laboratory collaboration in diagnostics

Transformative shifts in the in-vitro diagnostics quality control landscape are accelerating as innovation, digitalization, and regulatory evolution intersect. Emerging instrumentation platforms are delivering higher throughput and greater automation, which in turn demand more sophisticated control materials and reagent formulations to validate expanded dynamic ranges. Parallel to hardware advancement, software solutions for data management and quality assurance are maturing, enabling real-time monitoring and predictive analytics that change how laboratories approach process control and deviation management.

At the same time, the ascendancy of molecular diagnostics and immunoassays, accompanied by the proliferation of point-of-care testing, has diversified the types of controls needed to assure result integrity across settings. This diversification compels manufacturers and laboratories to rethink compatibility, calibration strategies, and cross-platform equivalence. Regulatory authorities are responding with more detailed guidance on validation and post-market surveillance, prompting stakeholders to integrate regulatory intelligence into product development lifecycles. Together, these shifts are reshaping procurement priorities, vendor relationships, and the skills required of laboratory personnel, driving a transition toward more collaborative and technology-enabled quality ecosystems.

Evaluating how 2025 United States tariff changes have influenced supply chain resilience, procurement strategy, and operational continuity for diagnostics quality control

The introduction of new tariffs in the United States during 2025 has introduced tangible ripple effects across supply chains, procurement strategies, and product cost structures relevant to quality control in in-vitro diagnostics. Suppliers of analyzers, control materials, reagents, and specialized software that rely on cross-border manufacturing and component sourcing are adjusting logistics and pricing models to mitigate margin pressure and maintain delivery reliability. In response, purchasing organizations and laboratory managers are reassessing supplier diversification and inventory strategies to preserve continuity of critical control materials and reagents.

Operationally, some manufacturers are accelerating efforts to localize production steps, redesign packaging for cost-efficiency, and reconfigure sourcing to minimize tariff exposure. These actions can improve resilience but may also introduce variability in lead times and qualification requirements as new production lines or alternative suppliers are validated. Importantly, the tariffs have underscored the value of transparent supplier data and traceability, reinforcing the need for rigorous lot-to-lot verification programs and comprehensive documentation. Collectively, these developments are prompting a reexamination of total cost of ownership and risk management practices, with stakeholders prioritizing strategic partnerships and supply chain visibility to maintain uninterrupted quality control operations.

Comprehensive segmentation insights tying product types technologies applications and end-user dynamics to operational priorities and supplier strategies

Segmentation-driven insights reveal nuanced value propositions and operational imperatives across product, technology, application, and end-user categories, each demanding tailored strategies from suppliers and laboratories. Based on product type, analyzers and instruments require attention to system interoperability and maintenance workflows, where automated systems drive throughput while semi-automated systems offer flexible, lower-volume deployment; control materials must satisfy stability and matrix-matching expectations, with liquid controls providing ready-to-use convenience and lyophilized controls offering extended shelf life; QC reagents call for validated performance across platforms; and software solutions spanning data management systems, laboratory information management systems, and dedicated QC software are increasingly central to harmonizing results and enabling audit-ready traceability.

From a technology perspective, clinical chemistry assays span colorimetric and turbidimetric modalities that place distinct demands on reagent presentation and calibration; hematology follows a split between automated cell counters and flow cytometry, influencing control complexity and verification protocols; immunoassays encompass chemiluminescence, ELISA, and fluorescence formats, each requiring tailored calibrators and interference testing; microbiology workflows differentiate between culture-based approaches and PCR techniques with divergent control needs; and molecular diagnostics-covering next-generation sequencing and PCR-necessitate highly specific controls to validate sensitivity, specificity, and library preparation steps. Application-focused segmentation highlights how cardiology testing emphasizes cardiac marker stability and point-of-care robustness, genetic testing hinges on carrier and prenatal assay accuracy, infectious disease testing requires bacterial and viral detection validation, oncology depends on minimal residual disease and tumor marker fidelity, and toxicology balances drugs of abuse screening with therapeutic drug monitoring precision. End-user segmentation illustrates divergent operational priorities across blood banks, diagnostic laboratories, hospitals and clinics, and research institutes, where national versus regional blood bank operations influence scale and inventory management, hospital-based versus independent laboratories differ in accreditation and workflow integration needs, clinic-level versus reference laboratory services vary in test breadth and turnaround expectations, and academic versus private research institutes balance exploratory assay development with rigorous control validation for publication and translational projects.

Taken together, these segmentation insights suggest that suppliers should prioritize modular product portfolios, validated cross-platform compatibility, and flexible service models, while laboratories should emphasize standardized verification protocols and integrated data strategies to manage complexity and ensure consistent diagnostic performance.

Regional dynamics and practical implications for procurement, validation, and adoption of quality control solutions across the Americas, EMEA, and Asia-Pacific

Regional dynamics shape procurement decisions, regulatory approaches, and adoption pathways for quality control solutions, with each geography presenting distinct drivers and constraints. The Americas exhibit a strong emphasis on consolidation of testing networks and investments in automation and digital quality tools to meet expectations for rapid turnaround and regulatory traceability. In contrast, Europe, the Middle East & Africa present a mosaic of regulatory regimes and infrastructure maturity, leading to a heterogeneous mix of centralized reference laboratories adopting high-complexity control systems and smaller facilities prioritizing cost-effective, robust controls and portable solutions for decentralized settings.

Meanwhile, the Asia-Pacific region is characterized by rapid adoption of novel diagnostic technologies, substantial investments in laboratory modernization, and a diverse supplier landscape that includes both global manufacturers and regionally specialized producers. Cross-regional trends are converging around interoperability, data standardization, and supply chain resilience, but implementation timelines and resource allocation differ substantially. Therefore, international suppliers and laboratory networks must tailor go-to-market approaches and validation packages to accommodate local regulatory frameworks, procurement cycles, and infrastructure capabilities to achieve effective and sustainable quality control integration across regions.

How leading companies are aligning integrated product portfolios service offerings and strategic partnerships to redefine quality control competitiveness

Leading companies in the in-vitro diagnostics quality control space are navigating a balance between technological innovation, strategic partnerships, and service differentiation to secure long-term customer relationships. Market leaders emphasize integrated offerings that combine calibrated control materials, compatible reagents, and cloud-enabled software to deliver seamless verification workflows and audit-ready reporting. Strategic collaborations with instrument manufacturers and clinical laboratories are common, enabling co-development of controls that address platform-specific performance characteristics and accelerate laboratory adoption.

In parallel, several firms are investing in enhanced manufacturing rigor and supply chain transparency to meet the increasing regulatory focus on traceability and lot-level documentation. Service-driven differentiation, such as tailored validation support, remote monitoring, and embedded training programs, is emerging as a critical value-add that reduces adoption friction and strengthens customer retention. Furthermore, smaller specialized players are focusing on niche segments-such as molecular diagnostics controls or point-of-care compatibility-to capitalize on growing assay complexity and unmet validation needs. Collectively, these approaches are reshaping competitive dynamics, with success increasingly tied to the ability to offer end-to-end solutions that align technical performance with practical laboratory workflows and regulatory expectations.

Practical prioritized actions to enhance supply chain resilience interoperability workforce capability and validation support for sustainable diagnostic quality control

Actionable recommendations for industry leaders center on strengthening supply chain resilience, enhancing interoperability, and investing in workforce capabilities to sustain high-quality diagnostics outputs. Manufacturers should prioritize modular design and cross-platform validation to reduce compatibility barriers and simplify procurement decisions for laboratories. In addition, increasing transparency around lot traceability and manufacturing provenance will address regulatory priorities and build trust among clinical customers. These measures should be complemented by scalable service models that include validation support, training, and remote monitoring to reduce time-to-competence for laboratory teams.

Laboratories and health systems should formalize control verification protocols that incorporate robust documentation and leverage advanced data management systems to detect subtle performance shifts. Procurement organizations ought to diversify supplier relationships and incorporate contingency planning into contracts to minimize disruption from geopolitical or tariff-related shocks. Investment in workforce development-particularly in informatics, assay validation, and quality assurance-will be essential to realize the benefits of automation and digital quality tools. Collectively, these recommendations aim to align technical, operational, and commercial priorities to ensure accurate, reliable, and compliant diagnostic results across diverse testing environments.

A rigorous mixed-methods approach combining interviews standards analysis and triangulated evidence to ensure practical and technical relevance in quality control insights

The research methodology combines primary qualitative inputs, secondary literature review, and a structured synthesis of technical and regulatory sources to produce a comprehensive assessment of quality control dynamics. Primary inputs include interviews with laboratory directors, quality managers, and product leaders to capture operational pain points, validation practices, and procurement considerations, supplemented by consultations with regulatory experts to interpret guidance and enforcement trends. Secondary sources comprise peer-reviewed literature, standards documentation, and publicly available regulatory communications that inform the technical underpinnings of control design and validation.

Analytical methods integrate thematic coding of interview data, cross-validation with documented standards, and comparative case analysis to surface patterns in supplier approaches, laboratory workflows, and regional adoption. Care has been taken to triangulate findings across multiple evidence streams, ensuring that conclusions reflect both practical experience and documented requirements. Limitations are acknowledged where proprietary data or nascent technologies constrain full visibility, and recommendations emphasize adaptive strategies that can be refined as new evidence emerges. Overall, the methodology aims to balance technical rigor with practical relevance for stakeholders involved in diagnostics quality control.

Summarizing why interoperability workforce investment and supply chain transparency will determine future reliability and compliance in diagnostics quality control

In conclusion, maintaining and advancing quality control practices in in-vitro diagnostics is a strategic imperative that underpins clinical confidence and regulatory compliance. The sector is experiencing rapid change driven by technological innovation, greater reliance on molecular and immunoassay modalities, and heightened expectations for data traceability and supply chain transparency. These forces are creating both challenges and opportunities: challenges in harmonizing cross-platform performance and securing resilient supply lines, and opportunities in leveraging digital tools, modular control products, and collaborative partnerships to streamline validation and monitoring.

Moving forward, stakeholders who embrace interoperability, invest in workforce capability, and adopt proactive supply chain and validation strategies will be best positioned to ensure consistent diagnostic performance and respond effectively to evolving regulatory requirements. The synthesis presented here offers a framework for prioritizing actions and aligning resources so that laboratories and manufacturers can deliver reliable, patient-centered diagnostic outcomes in a complex and rapidly evolving environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. In-Vitro Diagnostics Quality Control Market, by Product Type

  • 8.1. Analyzers & Instruments
    • 8.1.1. Automated Systems
    • 8.1.2. Semi-Automated Systems
  • 8.2. Control Materials
  • 8.3. QC Reagents
    • 8.3.1. Liquid Controls
    • 8.3.2. Lyophilized Controls
  • 8.4. Software Solutions
    • 8.4.1. Data Management Systems
    • 8.4.2. LIMS
    • 8.4.3. QC Software

9. In-Vitro Diagnostics Quality Control Market, by Technology

  • 9.1. Clinical Chemistry
    • 9.1.1. Colorimetric
    • 9.1.2. Turbidimetric
  • 9.2. Hematology
    • 9.2.1. Automated Cell Counters
    • 9.2.2. Flow Cytometry
  • 9.3. Immunoassay
    • 9.3.1. Chemiluminescence Immunoassay
    • 9.3.2. ELISA
    • 9.3.3. Fluorescence Immunoassay
  • 9.4. Microbiology
    • 9.4.1. Culture
    • 9.4.2. PCR
  • 9.5. Molecular Diagnostics
    • 9.5.1. Next-Generation Sequencing
    • 9.5.2. PCR

10. In-Vitro Diagnostics Quality Control Market, by Application

  • 10.1. Cardiology
    • 10.1.1. Cardiac Marker Testing
    • 10.1.2. Point-Of-Care Testing
  • 10.2. Genetic Testing
    • 10.2.1. Carrier Screening
    • 10.2.2. Prenatal Testing
  • 10.3. Infectious Disease Testing
    • 10.3.1. Bacterial Detection
    • 10.3.2. Viral Detection
  • 10.4. Oncology
    • 10.4.1. Minimal Residual Disease
    • 10.4.2. Tumor Marker Testing
  • 10.5. Toxicology
    • 10.5.1. Drugs Of Abuse
    • 10.5.2. Therapeutic Drug Monitoring

11. In-Vitro Diagnostics Quality Control Market, by End User

  • 11.1. Blood Banks
    • 11.1.1. National Blood Banks
    • 11.1.2. Regional Blood Banks
  • 11.2. Diagnostic Laboratories
    • 11.2.1. Hospital-Based Laboratories
    • 11.2.2. Independent Laboratories
  • 11.3. Hospitals & Clinics
    • 11.3.1. Clinic Laboratories
    • 11.3.2. Reference Laboratories
  • 11.4. Research Institutes
    • 11.4.1. Academic Institutes
    • 11.4.2. Private Research Laboratories

12. In-Vitro Diagnostics Quality Control Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. In-Vitro Diagnostics Quality Control Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. In-Vitro Diagnostics Quality Control Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States In-Vitro Diagnostics Quality Control Market

16. China In-Vitro Diagnostics Quality Control Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Becton, Dickinson and Company
  • 17.7. Bio-Rad Laboratories, Inc.
  • 17.8. Danaher Corporation
  • 17.9. Grifols, S.A.
  • 17.10. Microbix Biosystems Inc.
  • 17.11. QuidelOrtho Corporation
  • 17.12. Randox Laboratories Ltd.
  • 17.13. Roche Holding AG
  • 17.14. Seracare Life Sciences, Inc.
  • 17.15. Siemens Healthineers AG
  • 17.16. Sun Diagnostics, LLC
  • 17.17. Sysmex Corporation
  • 17.18. Thermo Fisher Scientific Inc.
  • 17.19. Werfen, S.A.
  • 17.20. ZeptoMetrix LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ANALYZERS & INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ANALYZERS & INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ANALYZERS & INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ANALYZERS & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CONTROL MATERIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CONTROL MATERIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CONTROL MATERIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LIQUID CONTROLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LIQUID CONTROLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LIQUID CONTROLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LYOPHILIZED CONTROLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LYOPHILIZED CONTROLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LYOPHILIZED CONTROLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SOFTWARE SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SOFTWARE SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SOFTWARE SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LIMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LIMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LIMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINICAL CHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINICAL CHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COLORIMETRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COLORIMETRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COLORIMETRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TURBIDIMETRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TURBIDIMETRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TURBIDIMETRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY AUTOMATED CELL COUNTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY AUTOMATED CELL COUNTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY AUTOMATED CELL COUNTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIAC MARKER TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIAC MARKER TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIAC MARKER TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY POINT-OF-CARE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY POINT-OF-CARE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BACTERIAL DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BACTERIAL DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BACTERIAL DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY VIRAL DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY VIRAL DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY VIRAL DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TUMOR MARKER TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TUMOR MARKER TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TUMOR MARKER TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TOXICOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TOXICOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TOXICOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DRUGS OF ABUSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DRUGS OF ABUSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DRUGS OF ABUSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY THERAPEUTIC DRUG MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY THERAPEUTIC DRUG MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY THERAPEUTIC DRUG MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BLOOD BANKS, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY NATIONAL BLOOD BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY NATIONAL BLOOD BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY NATIONAL BLOOD BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY REGIONAL BLOOD BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY REGIONAL BLOOD BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY REGIONAL BLOOD BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HOSPITAL-BASED LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HOSPITAL-BASED LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HOSPITAL-BASED LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 187. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ANALYZERS & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 189. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 190. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 191. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 193. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 195. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 200. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 201. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BLOOD BANKS, 2018-2032 (USD MILLION)
  • TABLE 205. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 207. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ANALYZERS & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BLOOD BANKS, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ANALYZERS & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 234. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 244. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BLOOD BANKS, 2018-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 250. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ANALYZERS & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY END USER,